Biogen announced on Wednesday that its total revenue for the fourth quarter of fiscal 2024 jumped 3% to $2.5 billion year-over-year. For the full 2024, revenue fell 2% to $9.7 billion.In its report, the company added that progress in the commercial portfolio continued in the last reported period, adding...
Although some of the most anticipated global players have already released their fresh financial results, this week investors' attention will turn to some of the leading Asian companies. Namely, SoftBank is expected to unveil its report on Wednesday, followed by Sony, Nissan, and Honda on Thursday.In...
Biogen Inc. announced on Wednesday that its total revenue for the third quarter of fiscal 2024 fell by 3% to $2.46 billion.According to the company's report, diluted earnings per share (EPS) for the three months reported came in at $2.66. Despite the year-over-year revenue decline, product...
American biotechnology firm Biogen Inc. disclosed on Tuesday that it saw $2.5 billion in revenue during the second quarter of fiscal 2024, marginally unchanged compared to the corresponding trimester last year. The figure stood slightly above market estimates.The company's net income dipped...
Biogen Inc. revealed on Wednesday in a press release that its total revenue in the first trimester of its fiscal 2024 amounted to $2.3 billion, down 7% compared to the same timeframe in 2023.Meanwhile, in the reported period, GAAP diluted earnings per share grew 1% year over year to reach $2.70....
American biotechnology firm Biogen Inc. disclosed on Tuesday that it booked $2.4 billion in revenue during the closing quarter for fiscal 2023, which marked a 6% drop compared to the corresponding trimester last year. The figure fell short of market estimates.
The company's net income fell 55%...
Market participants worldwide are bracing for another earnings-packed week as major global corporations prepare to publish quarterly reports in the coming days.
On February 13, The Coca-Cola Company, Biogen Inc., Robinhood Markets Inc., American International Group Inc. (AIG), and Lyft Inc. will...
Biogen Inc. announced on Wednesday that its revenue for the third quarter of 2023 amounted to $2.5 billion, an increase of 3% on a yearly basis, exceeding expectations. The biotech company said it recorded a net loss of $68.1 million this quarter, compared to a $1.1 billion income in the same...
Eisai Co. Ltd. and Biogen Inc. announced on Monday that Japanese authorities approved Leqembi, also known as lecanemab, their jointly produced treatment for Alzheimer's disease.
Japan became the second country to give the green light for the drug, after the United States Food and Drug...
Biogen Inc. will purchase Reata Pharmaceuticals Inc. for $7.3 billion in cash, with the transaction expected to close in the fourth quarter of 2023, the Massachusetts-based company announced on Friday.
"This is a unique opportunity for Biogen to bolster our near-term growth trajectory, and...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
